Clinical Trials Directory

Trials / Conditions / Locally Advanced Hepatocellular Carcinoma

Locally Advanced Hepatocellular Carcinoma

12 registered clinical trials studyying Locally Advanced Hepatocellular Carcinoma — 7 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingY-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Loca
NCT07511504
OHSU Knight Cancer InstitutePhase 2
RecruitingA Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
NCT06066138
National Cancer Institute (NCI)Phase 1
RecruitingHolmium-166 Transarterial Radioembolization for the Treatment of Hepatocellular Carcinoma
NCT06873269
Universitair Ziekenhuis Brussel—
RecruitingOlanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, He
NCT05705492
OHSU Knight Cancer InstitutePhase 2
TerminatedA Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezoliz
NCT05199285
Academic and Community Cancer Research UnitedPhase 2
WithdrawnYttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally A
NCT05327738
OHSU Knight Cancer InstitutePhase 2
RecruitingMultinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atez
NCT05377034
National Cancer Centre, SingaporePhase 2
RecruitingAtezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced,
NCT05168163
Academic and Community Cancer Research UnitedPhase 2
RecruitingPersonalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli
NCT05269381
Mayo ClinicPhase 1 / Phase 2
Active Not RecruitingDurvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver
NCT04605731
City of Hope Medical CenterPhase 1
CompletedNatural Killer (NK) Cell Therapy in Locally Advanced HCC
NCT05040438
Vaxcell Bio, Co., Ltd.Phase 2
CompletedFeasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resectio
NCT03299946
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 1